| Drug Study | ||
---|---|---|---|
Timepoint: | Enrolment | Session 1 | Session 2 |
Enrolment: | |||
 Eligibility screen | X |  |  |
 Informed consent | X | X |  |
 Condition Allocation | X |  |  |
Intervention: | |||
 Groups 1A & 1B Placebo |  | X |  |
 Groups 1A & 1B Lorazepam |  |  | X |
 Groups 2A & 2B Placebo |  |  | X |
 Groups 2A & 2B Lorazepam |  | X |  |
MRI: | |||
 Groups 1A & 2A fMRI Tasks (visual-motor) |  | X |  |
 Groups 1A & 2A fMRI Tasks (motor-visual) |  |  | X |
 Groups 1B & 2B fMRI Tasks (visual-motor) |  |  | X |
 Groups 1B & 2B fMRI Tasks (motor-visual) |  | X |  |
 All Groups fMRI Resting State |  | X | X |